Article
Treating complicated carbapenem-resistant enterobacteriaceae infections with ceftazidime/avibactam: a retrospective study with molecular strain characterisation.
International journal of antimicrobial agents - 1 Jun 2017
Krapp Fiorella, Grant Jennifer L, Sutton Sarah H, Ozer Egon A, Barr Viktorija O
Abstract excerpt
Ceftazidime/avibactam (CAZ/AVI) is the first antimicrobial agent with activity against carbapenem-resistant Enterobacteriaceae (CRE) approved by the US Food and Drug Administration (FDA). Notably, human clinical outcome data for this indication are limited. Therefore, a retrospective study was performed to evaluate the clinical outcomes and bacterial genomic characteristics of patients hospitalised at a tertiary...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
